pharvaris is a preclinical stage company focused on bringing an oral bradykinin b2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (hae) and other b2 receptor-mediated indications. the company reunites the core team responsible for the discovery and approval of the hae treatment icatibant. with novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Company profile
Ticker
PHVS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Pharvaris, B.V.
SEC CIK
PHVS stock data
Latest filings (excl ownership)
F-3ASR
Automatic shelf registration (foreign)
12 Apr 24
20-F
2023 FY
Annual report (foreign)
10 Apr 24
6-K
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
10 Apr 24
F-3ASR
Automatic shelf registration (foreign)
6 Mar 24
6-K
Current report (foreign)
6 Mar 24
6-K
Pharvaris Announces Extraordinary Meeting of Shareholders
16 Feb 24
6-K
Registration Rights Agreement
7 Feb 24
6-K
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
22 Jan 24
6-K
Current report (foreign)
8 Jan 24
6-K
Current report (foreign)
8 Dec 23
Latest ownership filings
144
Notice of proposed sale of securities
15 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
15 Mar 24
144/A
Notice of proposed sale of securities (amended)
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
80.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 606.76 bn |
Total shares | 43.07 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Investors | 4.78 mm | $99.86 bn |
General Atlantic | 4.41 mm | $91.96 bn |
venBio Global Strategic Fund III | 4.26 mm | $49.56 mm |
venBio Partners | 4.26 mm | $89.00 bn |
Foresite Capital Management IV | 3.74 mm | $78.13 bn |
LSP V Cooperatieve U.A. | 3.61 mm | $51.91 mm |
Foresite Capital Fund IV | 3.25 mm | $0.00 |
Viking Global Investors | 3.23 mm | $67.45 bn |
FMR | 3.21 mm | $66.94 bn |
Bain Capital Life Sciences Fund | 2.89 mm | $32.98 mm |
News
Morgan Stanley Maintains Overweight on Pharvaris, Lowers Price Target to $34
15 Apr 24
JMP Securities Maintains Market Outperform on Pharvaris, Raises Price Target to $50
11 Apr 24
Wedbush Reiterates Outperform on Pharvaris, Maintains $35 Price Target
11 Apr 24
Pharvaris Q4 EPS $(0.80) Misses $(0.58) Estimate
10 Apr 24
Pharvaris N.V. Q4 2023 EPS €(0.74) Vs €(1.16) YoY; Cash And Cash Equivalents Were ~€391 Million As Of December 31, 2023
10 Apr 24
Press releases
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
10 Apr 24
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
10 Apr 24
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
4 Apr 24
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
6 Mar 24
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
5 Mar 24